Regulatory Effects of Fenofibrate and Atorvastatin on lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome

Dick Chan, June Ji, Gerald Watts, A.G. Johnson, Esther Ooi, Hugh Barrett, K-A. Rye

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Subjects with the metabolic syndrome have reduced HDL cholesterol concentration and altered metabolism of high-density lipoprotein (Lp)A-I and LpA-I:A-II particles. In the metabolic syndrome, fenofibrate and atorvastatin may have differential effects on HDL particle kinetics. Eleven men with metabolic syndrome were studied in a randomized, double-blind, crossover trial of 5-week intervention periods with placebo, fenofibrate (200 mg/day), and atorvastatin (40 mg/day). LpA-I and LpA-I:A-II kinetics were examined using stable isotopic techniques and compartmental modeling. Compared with placebo, fenofibrate significantly increased the production of both LpA-I:A-II (30% increase; P <0.001) and apoA-II (43% increase; P <0.001), accounting for significant increases of their corresponding plasma concentrations (10 and 23% increases, respectively), but it did not alter LpA-I kinetics or concentration. Atorvastatin did not significantly alter HDL concentration or the kinetics of HDL particles. In the metabolic syndrome, fenofibrate, but not atorvastatin, influences HDL metabolism by increasing the transport of LpA-I:A-II particles.
Original languageEnglish
Pages (from-to)2111-2113
JournalDiabetes Care
Volume32
Issue number11
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Regulatory Effects of Fenofibrate and Atorvastatin on lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome'. Together they form a unique fingerprint.

Cite this